Medtronic plc (MDT)

Medtronic topped expectations on both the top and bottom line in preliminary results for the first fiscal quarter of 2027 (period ended July 31, 2026) reported September 1, 2026, with revenue up 13.7% to about $9.8 billion, driven by its broad medical technology portfolio across cardiac care, surgery, imaging, spine, and diabetes management. On the tape, revenue of $9.756 billion topped the $9.546 billion estimate (+2.2%), while adjusted EPS of $1.45 topped the $1.39 estimate (+4.3%) and rose 15.1% from $1.26 a year ago. Profitability held at a gross margin of about 65% and an operating margin near 18%, with gross profit of roughly $6.3 billion and operating income of about $1.8 billion. Net income climbed 41.3% to around $1.5 billion, up from $1.040 billion a year ago, alongside operating cash flow of about $1.8 billion, and the company paid roughly $921 million in dividends during the quarter. For the next period, consensus calls for EPS of $1.35 on revenue of $9.490 billion.